[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591729":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":60,"collaborators":10,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"HJN Sverige AB\u002FNeko Health","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patient_cohort",null,"Adult patients mainly from a primary care cohort. All patients visiting the clinical sites, seeking care, or as separately invited, are offered to participate in this investigation. This includes sub-groups of patients with hypertension, valvular disease or risk for IHD. All participants undergo at least one examination with the investigational device (Cardio P3) at initial visit.",[13],{"name":14,"affiliation":15,"role":16},"Henrik Hellqvist, MD","Neko Health AB","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Mattias Windå, MSc","CONTACT","+46703169040","mattias@nekohealth.com",[24,41,52],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Atrium Health Care Centre","RECRUITING","Stockholm","Sweden",{"type":30,"coordinates":31},"Point",[32,33],18.06871,59.32938,{"lat":33,"lon":32},[36,40],{"name":37,"role":20,"phone":38,"phoneExt":10,"email":39},"Andreea Valdman, MD","+4673 939 27 11","andreea@nekohealth.com",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":42,"status":26,"city":27,"state":10,"zip":10,"country":28,"cosmosGeoPoint":43,"geoPoint":45,"contacts":46},"Neko Health Centre, Regeringsgatan",{"type":30,"coordinates":44},[32,33],{"lat":33,"lon":32},[47,48,51],{"name":37,"role":20,"phone":38,"phoneExt":10,"email":39},{"name":49,"role":20,"phone":10,"phoneExt":10,"email":50},"Yuan Tan","yuan.tan@nekohealth.com",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"facility":53,"status":26,"city":27,"state":10,"zip":10,"country":28,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Neko Health Centre, Sibyllegatan",{"type":30,"coordinates":55},[32,33],{"lat":33,"lon":32},[58,59],{"name":37,"role":20,"phone":38,"phoneExt":10,"email":39},{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100591729",false,"NCT06984211","Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Cardio Alpha - Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Inclusion criteria:\n\n* Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease, e.g. infection\u002Fsepsis, severe COPD or metastatic cancers.\n* Patients unable to provide an informed consent",true,"ALL","18 Years",{"count":72,"type":73},8000,"ESTIMATED","OBSERVATIONAL","This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.\n\nThe main aims of the study are:\n\n1. To assess device and method performance for assessment of arterial stiffness and cardiovascular risk, on a prospective primary care cohort.\n2. To see if precision may be added in CVD risk assessment through a multi-modal approach, combining data on macro- and micro-circulatory function.",[77,78,79,80,81],"Hypertension","Ischemic Heart Disease","Valvular Heart Disease","Heart Failure","Diabetes","2025-05-19",{"date":84,"type":85},"2025-05-22","ACTUAL",{"date":87,"type":85},"2023-02-01",{"date":89,"type":73},"2026-02-01",{"name":5,"class":6},3]